nodes	percent_of_prediction	percent_of_DWPC	metapath
Metipranolol—Abnormal vision—Niacin—atherosclerosis	0.0183	0.0207	CcSEcCtD
Metipranolol—Arthritis—Lovastatin—atherosclerosis	0.0182	0.0207	CcSEcCtD
Metipranolol—Arthritis—Ezetimibe—atherosclerosis	0.0178	0.0203	CcSEcCtD
Metipranolol—Atrial fibrillation—Simvastatin—atherosclerosis	0.0175	0.0198	CcSEcCtD
Metipranolol—Bronchitis—Rosuvastatin—atherosclerosis	0.0173	0.0197	CcSEcCtD
Metipranolol—Arthritis—Simvastatin—atherosclerosis	0.017	0.0194	CcSEcCtD
Metipranolol—Atrial fibrillation—Niacin—atherosclerosis	0.016	0.0182	CcSEcCtD
Metipranolol—Arthritis—Niacin—atherosclerosis	0.0156	0.0178	CcSEcCtD
Metipranolol—Arthritis—Pravastatin—atherosclerosis	0.0154	0.0175	CcSEcCtD
Metipranolol—Rhinitis—Rosuvastatin—atherosclerosis	0.0145	0.0165	CcSEcCtD
Metipranolol—Bronchitis—Simvastatin—atherosclerosis	0.0138	0.0156	CcSEcCtD
Metipranolol—Angina pectoris—Niacin—atherosclerosis	0.0128	0.0145	CcSEcCtD
Metipranolol—Bronchitis—Niacin—atherosclerosis	0.0126	0.0144	CcSEcCtD
Metipranolol—Angina pectoris—Pravastatin—atherosclerosis	0.0126	0.0143	CcSEcCtD
Metipranolol—Acute coronary syndrome—Pravastatin—atherosclerosis	0.0114	0.0129	CcSEcCtD
Metipranolol—Myocardial infarction—Pravastatin—atherosclerosis	0.0113	0.0128	CcSEcCtD
Metipranolol—Cough—Rosuvastatin—atherosclerosis	0.011	0.0125	CcSEcCtD
Metipranolol—Myalgia—Rosuvastatin—atherosclerosis	0.0107	0.0122	CcSEcCtD
Metipranolol—Rhinitis—Niacin—atherosclerosis	0.0105	0.012	CcSEcCtD
Metipranolol—Rhinitis—Pravastatin—atherosclerosis	0.0104	0.0118	CcSEcCtD
Metipranolol—Visual impairment—Niacin—atherosclerosis	0.0101	0.0115	CcSEcCtD
Metipranolol—Vision blurred—Lovastatin—atherosclerosis	0.01	0.0114	CcSEcCtD
Metipranolol—Visual impairment—Pravastatin—atherosclerosis	0.00997	0.0113	CcSEcCtD
Metipranolol—Vision blurred—Simvastatin—atherosclerosis	0.00939	0.0107	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.00935	0.0106	CcSEcCtD
Metipranolol—Palpitations—Ezetimibe—atherosclerosis	0.00923	0.0105	CcSEcCtD
Metipranolol—Cough—Ezetimibe—atherosclerosis	0.00912	0.0104	CcSEcCtD
Metipranolol—Myalgia—Lovastatin—atherosclerosis	0.00907	0.0103	CcSEcCtD
Metipranolol—Anxiety—Lovastatin—atherosclerosis	0.00904	0.0103	CcSEcCtD
Metipranolol—Hypertension—Ezetimibe—atherosclerosis	0.00902	0.0103	CcSEcCtD
Metipranolol—Tension—Niacin—atherosclerosis	0.00898	0.0102	CcSEcCtD
Metipranolol—Discomfort—Lovastatin—atherosclerosis	0.00896	0.0102	CcSEcCtD
Metipranolol—Myalgia—Ezetimibe—atherosclerosis	0.00889	0.0101	CcSEcCtD
Metipranolol—Nervousness—Niacin—atherosclerosis	0.00888	0.0101	CcSEcCtD
Metipranolol—Tension—Pravastatin—atherosclerosis	0.00884	0.01	CcSEcCtD
Metipranolol—Discomfort—Ezetimibe—atherosclerosis	0.00879	0.00999	CcSEcCtD
Metipranolol—Nervousness—Pravastatin—atherosclerosis	0.00875	0.00995	CcSEcCtD
Metipranolol—Vision blurred—Niacin—atherosclerosis	0.00862	0.0098	CcSEcCtD
Metipranolol—Vision blurred—Pravastatin—atherosclerosis	0.00849	0.00965	CcSEcCtD
Metipranolol—Myalgia—Simvastatin—atherosclerosis	0.00848	0.00964	CcSEcCtD
Metipranolol—Anxiety—Simvastatin—atherosclerosis	0.00845	0.00961	CcSEcCtD
Metipranolol—Discomfort—Simvastatin—atherosclerosis	0.00838	0.00953	CcSEcCtD
Metipranolol—Oedema—Simvastatin—atherosclerosis	0.00813	0.00924	CcSEcCtD
Metipranolol—Palpitations—Niacin—atherosclerosis	0.00808	0.00919	CcSEcCtD
Metipranolol—Cough—Niacin—atherosclerosis	0.00798	0.00907	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.00792	0.009	CcSEcCtD
Metipranolol—Cough—Pravastatin—atherosclerosis	0.00786	0.00894	CcSEcCtD
Metipranolol—Myalgia—Niacin—atherosclerosis	0.00779	0.00885	CcSEcCtD
Metipranolol—Hypertension—Pravastatin—atherosclerosis	0.00778	0.00884	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.00777	0.00883	CcSEcCtD
Metipranolol—Dyspnoea—Lovastatin—atherosclerosis	0.00775	0.00881	CcSEcCtD
Metipranolol—Myalgia—Pravastatin—atherosclerosis	0.00767	0.00872	CcSEcCtD
Metipranolol—Anxiety—Pravastatin—atherosclerosis	0.00764	0.00869	CcSEcCtD
Metipranolol—Dyspnoea—Ezetimibe—atherosclerosis	0.0076	0.00864	CcSEcCtD
Metipranolol—Discomfort—Pravastatin—atherosclerosis	0.00758	0.00861	CcSEcCtD
Metipranolol—Hypersensitivity—Rosuvastatin—atherosclerosis	0.00756	0.00859	CcSEcCtD
Metipranolol—Oedema—Niacin—atherosclerosis	0.00747	0.00849	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.00741	0.00842	CcSEcCtD
Metipranolol—Asthenia—Rosuvastatin—atherosclerosis	0.00736	0.00837	CcSEcCtD
Metipranolol—Oedema—Pravastatin—atherosclerosis	0.00735	0.00836	CcSEcCtD
Metipranolol—Dyspnoea—Simvastatin—atherosclerosis	0.00725	0.00824	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Niacin—atherosclerosis	0.0068	0.00773	CcSEcCtD
Metipranolol—Dizziness—Rosuvastatin—atherosclerosis	0.00678	0.00771	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.0067	0.00761	CcSEcCtD
Metipranolol—Dyspnoea—Niacin—atherosclerosis	0.00666	0.00757	CcSEcCtD
Metipranolol—Somnolence—Niacin—atherosclerosis	0.00664	0.00755	CcSEcCtD
Metipranolol—Dyspnoea—Pravastatin—atherosclerosis	0.00655	0.00745	CcSEcCtD
Metipranolol—Rash—Rosuvastatin—atherosclerosis	0.00647	0.00735	CcSEcCtD
Metipranolol—Dermatitis—Rosuvastatin—atherosclerosis	0.00646	0.00735	CcSEcCtD
Metipranolol—Headache—Rosuvastatin—atherosclerosis	0.00643	0.00731	CcSEcCtD
Metipranolol—Hypersensitivity—Lovastatin—atherosclerosis	0.0064	0.00728	CcSEcCtD
Metipranolol—Hypersensitivity—Ezetimibe—atherosclerosis	0.00628	0.00714	CcSEcCtD
Metipranolol—Asthenia—Lovastatin—atherosclerosis	0.00624	0.00709	CcSEcCtD
Metipranolol—Asthenia—Ezetimibe—atherosclerosis	0.00612	0.00695	CcSEcCtD
Metipranolol—Nausea—Rosuvastatin—atherosclerosis	0.00609	0.00693	CcSEcCtD
Metipranolol—Hypersensitivity—Simvastatin—atherosclerosis	0.00599	0.00681	CcSEcCtD
Metipranolol—Asthenia—Simvastatin—atherosclerosis	0.00583	0.00663	CcSEcCtD
Metipranolol—Dizziness—Lovastatin—atherosclerosis	0.00575	0.00653	CcSEcCtD
Metipranolol—Dizziness—Ezetimibe—atherosclerosis	0.00564	0.00641	CcSEcCtD
Metipranolol—Hypersensitivity—Niacin—atherosclerosis	0.0055	0.00625	CcSEcCtD
Metipranolol—Rash—Lovastatin—atherosclerosis	0.00548	0.00623	CcSEcCtD
Metipranolol—Dermatitis—Lovastatin—atherosclerosis	0.00548	0.00623	CcSEcCtD
Metipranolol—Headache—Lovastatin—atherosclerosis	0.00545	0.00619	CcSEcCtD
Metipranolol—Hypersensitivity—Pravastatin—atherosclerosis	0.00542	0.00616	CcSEcCtD
Metipranolol—Dizziness—Simvastatin—atherosclerosis	0.00538	0.00611	CcSEcCtD
Metipranolol—Rash—Ezetimibe—atherosclerosis	0.00538	0.00611	CcSEcCtD
Metipranolol—Dermatitis—Ezetimibe—atherosclerosis	0.00537	0.00611	CcSEcCtD
Metipranolol—Asthenia—Niacin—atherosclerosis	0.00536	0.00609	CcSEcCtD
Metipranolol—Headache—Ezetimibe—atherosclerosis	0.00534	0.00607	CcSEcCtD
Metipranolol—Asthenia—Pravastatin—atherosclerosis	0.00527	0.006	CcSEcCtD
Metipranolol—Nausea—Lovastatin—atherosclerosis	0.00516	0.00587	CcSEcCtD
Metipranolol—Rash—Simvastatin—atherosclerosis	0.00513	0.00583	CcSEcCtD
Metipranolol—Dermatitis—Simvastatin—atherosclerosis	0.00512	0.00582	CcSEcCtD
Metipranolol—Headache—Simvastatin—atherosclerosis	0.00509	0.00579	CcSEcCtD
Metipranolol—Nausea—Ezetimibe—atherosclerosis	0.00506	0.00576	CcSEcCtD
Metipranolol—Dizziness—Niacin—atherosclerosis	0.00494	0.00561	CcSEcCtD
Metipranolol—Dizziness—Pravastatin—atherosclerosis	0.00486	0.00553	CcSEcCtD
Metipranolol—Nausea—Simvastatin—atherosclerosis	0.00483	0.00549	CcSEcCtD
Metipranolol—Rash—Niacin—atherosclerosis	0.00471	0.00535	CcSEcCtD
Metipranolol—Dermatitis—Niacin—atherosclerosis	0.0047	0.00535	CcSEcCtD
Metipranolol—Headache—Niacin—atherosclerosis	0.00468	0.00532	CcSEcCtD
Metipranolol—Rash—Pravastatin—atherosclerosis	0.00463	0.00527	CcSEcCtD
Metipranolol—Dermatitis—Pravastatin—atherosclerosis	0.00463	0.00526	CcSEcCtD
Metipranolol—Headache—Pravastatin—atherosclerosis	0.00461	0.00524	CcSEcCtD
Metipranolol—Nausea—Niacin—atherosclerosis	0.00443	0.00504	CcSEcCtD
Metipranolol—Nausea—Pravastatin—atherosclerosis	0.00437	0.00496	CcSEcCtD
Metipranolol—ADRB1—GPCR ligand binding—CX3CL1—atherosclerosis	0.000536	0.00445	CbGpPWpGaD
Metipranolol—ADRB2—GPCR ligand binding—CX3CR1—atherosclerosis	0.000534	0.00444	CbGpPWpGaD
Metipranolol—ADRB2—GPCR ligand binding—CASR—atherosclerosis	0.000534	0.00444	CbGpPWpGaD
Metipranolol—ADRB2—GPCR ligand binding—CX3CL1—atherosclerosis	0.000524	0.00435	CbGpPWpGaD
Metipranolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCR2—atherosclerosis	0.000518	0.00431	CbGpPWpGaD
Metipranolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—EDNRA—atherosclerosis	0.000518	0.00431	CbGpPWpGaD
Metipranolol—ADRB1—GPCRs, Class A Rhodopsin-like—AGTR1—atherosclerosis	0.000515	0.00427	CbGpPWpGaD
Metipranolol—ADRB1—GPCR ligand binding—CNR2—atherosclerosis	0.000508	0.00422	CbGpPWpGaD
Metipranolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCR2—atherosclerosis	0.000507	0.00421	CbGpPWpGaD
Metipranolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—EDNRA—atherosclerosis	0.000507	0.00421	CbGpPWpGaD
Metipranolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—GHRL—atherosclerosis	0.000505	0.0042	CbGpPWpGaD
Metipranolol—ADRB2—GPCRs, Class A Rhodopsin-like—AGTR1—atherosclerosis	0.000503	0.00418	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—HRH1—atherosclerosis	0.0005	0.00415	CbGpPWpGaD
Metipranolol—ADRB2—GPCR ligand binding—CNR2—atherosclerosis	0.000497	0.00413	CbGpPWpGaD
Metipranolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—GHRL—atherosclerosis	0.000494	0.00411	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—HRH1—atherosclerosis	0.000489	0.00406	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—HRH1—atherosclerosis	0.000454	0.00377	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—HRH1—atherosclerosis	0.000444	0.00369	CbGpPWpGaD
Metipranolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—KNG1—atherosclerosis	0.000443	0.00368	CbGpPWpGaD
Metipranolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—AGTR1—atherosclerosis	0.000441	0.00366	CbGpPWpGaD
Metipranolol—ADRB1—GPCR ligand binding—CCL3—atherosclerosis	0.000437	0.00363	CbGpPWpGaD
Metipranolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—KNG1—atherosclerosis	0.000434	0.0036	CbGpPWpGaD
Metipranolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—AGTR1—atherosclerosis	0.000431	0.00358	CbGpPWpGaD
Metipranolol—ADRB2—GPCR ligand binding—CCL3—atherosclerosis	0.000427	0.00355	CbGpPWpGaD
Metipranolol—ADRB1—GPCR ligand binding—EDNRA—atherosclerosis	0.000395	0.00328	CbGpPWpGaD
Metipranolol—ADRB1—GPCR ligand binding—CCR2—atherosclerosis	0.000395	0.00328	CbGpPWpGaD
Metipranolol—ADRB2—GPCR ligand binding—EDNRA—atherosclerosis	0.000386	0.00321	CbGpPWpGaD
Metipranolol—ADRB2—GPCR ligand binding—CCR2—atherosclerosis	0.000386	0.00321	CbGpPWpGaD
Metipranolol—ADRB1—GPCR ligand binding—GHRL—atherosclerosis	0.000385	0.0032	CbGpPWpGaD
Metipranolol—ADRB2—GPCR ligand binding—GHRL—atherosclerosis	0.000376	0.00313	CbGpPWpGaD
Metipranolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—EDN1—atherosclerosis	0.000374	0.0031	CbGpPWpGaD
Metipranolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL5—atherosclerosis	0.000371	0.00308	CbGpPWpGaD
Metipranolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—EDN1—atherosclerosis	0.000366	0.00304	CbGpPWpGaD
Metipranolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL5—atherosclerosis	0.000363	0.00301	CbGpPWpGaD
Metipranolol—ADRB1—GPCR ligand binding—KNG1—atherosclerosis	0.000338	0.00281	CbGpPWpGaD
Metipranolol—ADRB1—GPCR ligand binding—AGTR1—atherosclerosis	0.000336	0.00279	CbGpPWpGaD
Metipranolol—ADRB2—GPCR ligand binding—KNG1—atherosclerosis	0.00033	0.00274	CbGpPWpGaD
Metipranolol—ADRB2—GPCR ligand binding—AGTR1—atherosclerosis	0.000328	0.00273	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—CCL4—atherosclerosis	0.000328	0.00272	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—UTS2—atherosclerosis	0.000322	0.00267	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—CCL4—atherosclerosis	0.000321	0.00267	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—UTS2—atherosclerosis	0.000315	0.00262	CbGpPWpGaD
Metipranolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—AGT—atherosclerosis	0.00031	0.00258	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—CASR—atherosclerosis	0.000309	0.00256	CbGpPWpGaD
Metipranolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—AGT—atherosclerosis	0.000303	0.00252	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—CASR—atherosclerosis	0.000302	0.00251	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—UTS2—atherosclerosis	0.000292	0.00243	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—CNR2—atherosclerosis	0.000287	0.00238	CbGpPWpGaD
Metipranolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—F2—atherosclerosis	0.000287	0.00238	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—UTS2—atherosclerosis	0.000286	0.00238	CbGpPWpGaD
Metipranolol—ADRB1—GPCR ligand binding—EDN1—atherosclerosis	0.000285	0.00236	CbGpPWpGaD
Metipranolol—ADRB1—GPCR ligand binding—CCL5—atherosclerosis	0.000282	0.00235	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—CNR2—atherosclerosis	0.000281	0.00233	CbGpPWpGaD
Metipranolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—F2—atherosclerosis	0.00028	0.00233	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—CX3CR1—atherosclerosis	0.00028	0.00233	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—CASR—atherosclerosis	0.00028	0.00233	CbGpPWpGaD
Metipranolol—ADRB2—GPCR ligand binding—EDN1—atherosclerosis	0.000278	0.00231	CbGpPWpGaD
Metipranolol—ADRB2—GPCR ligand binding—CCL5—atherosclerosis	0.000276	0.00229	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—CX3CL1—atherosclerosis	0.000275	0.00228	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—CX3CR1—atherosclerosis	0.000274	0.00228	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—CASR—atherosclerosis	0.000274	0.00228	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—CX3CL1—atherosclerosis	0.000269	0.00223	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—HRH1—atherosclerosis	0.000268	0.00223	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—HRH1—atherosclerosis	0.000262	0.00218	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—CNR2—atherosclerosis	0.000261	0.00216	CbGpPWpGaD
Metipranolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL2—atherosclerosis	0.000255	0.00212	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—CNR2—atherosclerosis	0.000255	0.00212	CbGpPWpGaD
Metipranolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL2—atherosclerosis	0.00025	0.00208	CbGpPWpGaD
Metipranolol—ADRB1—GPCR ligand binding—AGT—atherosclerosis	0.000236	0.00196	CbGpPWpGaD
Metipranolol—ADRB2—GPCR ligand binding—AGT—atherosclerosis	0.000231	0.00192	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—CCL3—atherosclerosis	0.000224	0.00186	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—EDNRA—atherosclerosis	0.000223	0.00185	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—CCR2—atherosclerosis	0.000223	0.00185	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—CCL3—atherosclerosis	0.000219	0.00182	CbGpPWpGaD
Metipranolol—ADRB1—GPCR ligand binding—F2—atherosclerosis	0.000218	0.00181	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—CCR2—atherosclerosis	0.000218	0.00181	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—EDNRA—atherosclerosis	0.000218	0.00181	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—GHRL—atherosclerosis	0.000217	0.00181	CbGpPWpGaD
Metipranolol—ADRB2—GPCR ligand binding—F2—atherosclerosis	0.000214	0.00177	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—GHRL—atherosclerosis	0.000213	0.00177	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—APOA4—atherosclerosis	0.00021	0.00175	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—APOA4—atherosclerosis	0.000206	0.00171	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—EDNRA—atherosclerosis	0.000203	0.00168	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—CCR2—atherosclerosis	0.000203	0.00168	CbGpPWpGaD
Metipranolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL8—atherosclerosis	0.000202	0.00168	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—CCR2—atherosclerosis	0.000198	0.00165	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—EDNRA—atherosclerosis	0.000198	0.00165	CbGpPWpGaD
Metipranolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL8—atherosclerosis	0.000198	0.00164	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—GHRL—atherosclerosis	0.000197	0.00164	CbGpPWpGaD
Metipranolol—ADRB1—GPCR ligand binding—CCL2—atherosclerosis	0.000195	0.00162	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CCL4—atherosclerosis	0.000194	0.00161	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—GHRL—atherosclerosis	0.000193	0.0016	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—KNG1—atherosclerosis	0.000191	0.00159	CbGpPWpGaD
Metipranolol—ADRB2—GPCR ligand binding—CCL2—atherosclerosis	0.00019	0.00158	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—AGTR1—atherosclerosis	0.00019	0.00158	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CCL4—atherosclerosis	0.00019	0.00157	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—KNG1—atherosclerosis	0.000187	0.00155	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—AGTR1—atherosclerosis	0.000186	0.00154	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—APOA2—atherosclerosis	0.000181	0.0015	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—APOA2—atherosclerosis	0.000177	0.00147	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—KNG1—atherosclerosis	0.000173	0.00144	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—UTS2—atherosclerosis	0.000173	0.00143	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—AGTR1—atherosclerosis	0.000172	0.00143	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—KNG1—atherosclerosis	0.00017	0.00141	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—UTS2—atherosclerosis	0.000169	0.0014	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—AGTR1—atherosclerosis	0.000169	0.0014	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CX3CR1—atherosclerosis	0.000166	0.00138	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CASR—atherosclerosis	0.000166	0.00138	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CX3CL1—atherosclerosis	0.000162	0.00135	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CASR—atherosclerosis	0.000162	0.00135	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CX3CR1—atherosclerosis	0.000162	0.00135	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—EDN1—atherosclerosis	0.000161	0.00134	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—CCL5—atherosclerosis	0.00016	0.00133	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CX3CL1—atherosclerosis	0.000159	0.00132	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—EDN1—atherosclerosis	0.000157	0.00131	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—CCL5—atherosclerosis	0.000156	0.0013	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CNR2—atherosclerosis	0.000154	0.00128	CbGpPWpGaD
Metipranolol—ADRB1—GPCR ligand binding—CXCL8—atherosclerosis	0.000154	0.00128	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—MMP3—atherosclerosis	0.000154	0.00128	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—PRKCG—atherosclerosis	0.000152	0.00126	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CNR2—atherosclerosis	0.000151	0.00125	CbGpPWpGaD
Metipranolol—ADRB2—GPCR ligand binding—CXCL8—atherosclerosis	0.00015	0.00125	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—MMP3—atherosclerosis	0.00015	0.00125	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—PRKCG—atherosclerosis	0.000148	0.00123	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—EDN1—atherosclerosis	0.000146	0.00121	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—CCL5—atherosclerosis	0.000145	0.0012	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—EDN1—atherosclerosis	0.000143	0.00119	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—CCL5—atherosclerosis	0.000142	0.00118	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—PRKCG—atherosclerosis	0.000138	0.00114	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—VWF—atherosclerosis	0.000137	0.00114	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—APOC3—atherosclerosis	0.000136	0.00113	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—LDLR—atherosclerosis	0.000136	0.00113	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—PRKCG—atherosclerosis	0.000135	0.00112	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—VWF—atherosclerosis	0.000134	0.00111	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—AGT—atherosclerosis	0.000134	0.00111	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—APOC3—atherosclerosis	0.000133	0.00111	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—LDLR—atherosclerosis	0.000133	0.0011	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CCL3—atherosclerosis	0.000132	0.0011	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—AGT—atherosclerosis	0.000131	0.00108	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CCL3—atherosclerosis	0.000129	0.00108	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—NCF1—atherosclerosis	0.000127	0.00105	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—NCF1—atherosclerosis	0.000124	0.00103	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—F2—atherosclerosis	0.000123	0.00102	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—AGT—atherosclerosis	0.000121	0.00101	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—F2—atherosclerosis	0.000121	0.001	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CCR2—atherosclerosis	0.00012	0.000994	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—EDNRA—atherosclerosis	0.00012	0.000994	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CYBA—atherosclerosis	0.000119	0.00099	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—AGT—atherosclerosis	0.000119	0.000985	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—PIK3CG—atherosclerosis	0.000118	0.000981	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CCR2—atherosclerosis	0.000117	0.000973	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—EDNRA—atherosclerosis	0.000117	0.000973	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PARP1—atherosclerosis	0.000117	0.000969	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—GHRL—atherosclerosis	0.000117	0.000969	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PLAT—atherosclerosis	0.000117	0.000969	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CYBA—atherosclerosis	0.000117	0.000968	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—PIK3CG—atherosclerosis	0.000115	0.000959	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—GHRL—atherosclerosis	0.000114	0.000948	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PARP1—atherosclerosis	0.000114	0.000948	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PLAT—atherosclerosis	0.000114	0.000948	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—F2—atherosclerosis	0.000112	0.000931	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—F2—atherosclerosis	0.00011	0.00091	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—PIK3CG—atherosclerosis	0.000107	0.000891	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—PIK3CG—atherosclerosis	0.000105	0.000871	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—KNG1—atherosclerosis	0.000102	0.000851	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—AGTR1—atherosclerosis	0.000102	0.000845	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—KNG1—atherosclerosis	0.0001	0.000832	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—CCL2—atherosclerosis	9.98e-05	0.000829	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—AGTR1—atherosclerosis	9.96e-05	0.000827	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PLG—atherosclerosis	9.92e-05	0.000824	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—CCL2—atherosclerosis	9.77e-05	0.000811	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PLG—atherosclerosis	9.7e-05	0.000806	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—SOCS3—atherosclerosis	9.39e-05	0.00078	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—SOCS3—atherosclerosis	9.19e-05	0.000763	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—MMP3—atherosclerosis	9.07e-05	0.000754	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—IGF2—atherosclerosis	9.03e-05	0.00075	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—MMP3—atherosclerosis	8.87e-05	0.000737	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—IGF2—atherosclerosis	8.83e-05	0.000734	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—APOB—atherosclerosis	8.77e-05	0.000728	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—CXCL8—atherosclerosis	8.69e-05	0.000722	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—EDN1—atherosclerosis	8.63e-05	0.000717	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—APOB—atherosclerosis	8.58e-05	0.000712	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CCL5—atherosclerosis	8.56e-05	0.000711	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—CXCL8—atherosclerosis	8.5e-05	0.000706	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—EDN1—atherosclerosis	8.44e-05	0.000701	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CCL5—atherosclerosis	8.37e-05	0.000696	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—LPL—atherosclerosis	8.37e-05	0.000695	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—LPL—atherosclerosis	8.19e-05	0.00068	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PRKCG—atherosclerosis	8.14e-05	0.000676	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PRKCG—atherosclerosis	7.96e-05	0.000661	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—SPP1—atherosclerosis	7.93e-05	0.000659	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—CXCL8—atherosclerosis	7.89e-05	0.000656	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—SPP1—atherosclerosis	7.76e-05	0.000644	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—CXCL8—atherosclerosis	7.72e-05	0.000641	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PDGFB—atherosclerosis	7.34e-05	0.000609	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PDGFB—atherosclerosis	7.18e-05	0.000596	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—AGT—atherosclerosis	7.16e-05	0.000595	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—LEP—atherosclerosis	7.02e-05	0.000583	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—APOE—atherosclerosis	7.02e-05	0.000583	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—AGT—atherosclerosis	7.01e-05	0.000582	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CAV1—atherosclerosis	6.95e-05	0.000578	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—APOA1—atherosclerosis	6.94e-05	0.000576	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—APOE—atherosclerosis	6.86e-05	0.00057	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—LEP—atherosclerosis	6.86e-05	0.00057	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CAV1—atherosclerosis	6.8e-05	0.000565	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—APOA1—atherosclerosis	6.79e-05	0.000564	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—ESR1—atherosclerosis	6.7e-05	0.000557	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—F2—atherosclerosis	6.62e-05	0.00055	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—ESR1—atherosclerosis	6.55e-05	0.000544	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—F2—atherosclerosis	6.47e-05	0.000538	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PIK3CG—atherosclerosis	6.33e-05	0.000526	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PIK3CG—atherosclerosis	6.19e-05	0.000515	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—MAPK3—atherosclerosis	6.06e-05	0.000504	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—INS—atherosclerosis	5.99e-05	0.000498	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—MAPK3—atherosclerosis	5.93e-05	0.000493	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CCL2—atherosclerosis	5.9e-05	0.00049	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—INS—atherosclerosis	5.86e-05	0.000487	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—IGF1—atherosclerosis	5.8e-05	0.000482	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CCL2—atherosclerosis	5.77e-05	0.000479	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—IGF1—atherosclerosis	5.67e-05	0.000471	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—SERPINE1—atherosclerosis	5.51e-05	0.000457	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—SERPINE1—atherosclerosis	5.39e-05	0.000447	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—NOS3—atherosclerosis	5.26e-05	0.000437	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—NOS3—atherosclerosis	5.14e-05	0.000427	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CXCL8—atherosclerosis	4.66e-05	0.000387	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CXCL8—atherosclerosis	4.56e-05	0.000379	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—AKT1—atherosclerosis	4.5e-05	0.000374	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—IL6—atherosclerosis	4.43e-05	0.000368	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—AKT1—atherosclerosis	4.41e-05	0.000366	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—IL6—atherosclerosis	4.34e-05	0.00036	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—MMP9—atherosclerosis	4.22e-05	0.00035	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—NFKB1—atherosclerosis	4.17e-05	0.000347	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—MMP9—atherosclerosis	4.13e-05	0.000343	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—MAPK8—atherosclerosis	4.1e-05	0.000341	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—AKT1—atherosclerosis	4.09e-05	0.00034	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—NFKB1—atherosclerosis	4.08e-05	0.000339	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—MAPK8—atherosclerosis	4.01e-05	0.000333	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—AKT1—atherosclerosis	4e-05	0.000332	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—VEGFA—atherosclerosis	3.79e-05	0.000315	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—STAT3—atherosclerosis	3.75e-05	0.000312	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—VEGFA—atherosclerosis	3.7e-05	0.000308	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—STAT3—atherosclerosis	3.67e-05	0.000305	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—MAPK3—atherosclerosis	3.58e-05	0.000298	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—MAPK3—atherosclerosis	3.5e-05	0.000291	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—TGFB1—atherosclerosis	3.48e-05	0.000289	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—TGFB1—atherosclerosis	3.4e-05	0.000282	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—IL6—atherosclerosis	2.62e-05	0.000218	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—IL6—atherosclerosis	2.56e-05	0.000213	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—AKT1—atherosclerosis	2.42e-05	0.000201	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—AKT1—atherosclerosis	2.36e-05	0.000196	CbGpPWpGaD
